Hence, our study underscores a protective role of albumin in patients with CLDs and in KCs stimulated by the bacterial products, suggesting that albumin therapies aim to not only improve plasma osmolality for patients with CLDs but benefit KCs in reducing the damage from microbial products, providing a convincing rationale for albumin application in patients with CLDs. The gene discussed is ALB; the disease is dry eye syndrome.